Publicly funded practice-oriented clinical trials: of importance for healthcare payers
Abstract
Aim: Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials. Methodology: A literature search including publications on institutions’ websites was performed and supplemented with information gathered from (inter)national stakeholders. Results: Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest. The available literature suggests publicly funded research programs could provide a positive return on investment. The main hurdles (e.g., sufficient funding and absence of equipoise) and success factors (e.g., selection of research questions and research infrastructure) for the successful conduct of publicly funded trials were identified. Conclusion: Governments should see public funding of pragmatic practice-oriented clinical trials as a good opportunity to improve the selection and quality of treatments and stimulate efficient use of limited resources.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Neyt M, Christiaens T, Demotes J, Hulstaert F. Publicly funded practice-oriented clinical trials. Health Services Research (HSR) (KCE Reports 246), (2015). https://kce.fgov.be/publication/report/publicly-funded-practice-oriented-clinical-trials#.V4d4N9fF06Y.
2.
Banzi R, Moja L, Pistotti V, Facchini A, Liberati A. Conceptual frameworks and empirical approaches used to assess the impact of health research: an overview of reviews. Health Res. Policy Syst. 9, 26 (2011).
• Article on how to assess the impact of research to understand the value of investments and to increase accountability.
3.
Johnson KE, Tachibana C, Coronado GD et al. A guide to research partnerships for pragmatic clinical trials. BMJ 349, g6826 (2014).
4.
Clinical and Translational Science Award. www.ctsacentral.org.
5.
The James Lind Alliance. www.lindalliance.org.
6.
NIHR Evaluation, Trials and Studies. www.nets.nihr.ac.uk.
7.
8.
Patient-Centered Outcomes Research Institute. www.pcori.org.
9.
The Health Maintenance Organisation Research Network. www.hcsrn.org/en/.
10.
NHS. www.nhs.uk.
11.
The Netherlands Organisation for Health Research and Development. www.zonmw.nl/nl/.
12.
European Medicines Agency (EMA). Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf.
13.
Organisation for Economic Co-Operation and Development (OECD) Global Science Forum. Facilitating International Co-operation in Non-Commercial Clinical Trials (2011). www.oecd.org/sti/sci-tech/49344626.pdf.
14.
Hulstaert F, Neyt M, Vinck I et al. The pre-market clinical evaluation of innovative high-risk medical devices. Health Services Research (HSR) (D/2011/10.273/31), (2011). https://kce.fgov.be/sites/default/files/page_documents/kce_158c_innovative_high-risk_medical_devices_0.pdf.
15.
Hulstaert F, Neyt M, Vinck I et al. Pre-market clinical evaluations of innovative high-risk medical devices in Europe. Int. J. Technol. Assess. Health Care 28(3), 278–284 (2012).
16.
Van Den Bulcke M, San Miguel L, Salgado R et al. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology. Health Technology Assessment (HTA) (D/2015/10.273/26), (2015). https://kce.fgov.be/sites/default/files/page_documents/KCE_240_NGS_targeted_therapy_Report.pdf.
17.
Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme. Information for primary care. PSA testing in asymptomatic men (2010). www.gov.scot/resource/doc/1094/0088915.pdf.
18.
Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol. Assess. 7(14), 1–88 (2003).
19.
Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 347, f5577 (2013).
20.
Roback K, Dalal K, Carlsson P. Evaluation of health research: measuring costs and socioeconomic effects. Int. J. Preventive Med. 2(4), 203–215 (2011).
21.
Roth JA, Etzioni R, Waters TM et al. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann. Intern. Med. 160(9), 594–602 (2014).
•• Example of a publicly funded trial with a substantial return on investment.
22.
Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321–333 (2002).
23.
Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1), 47–53 (2004).
24.
Kim N, Gross C, Curtis J et al. The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J. Gen. Intern. Med. 20(11), 1026–1031 (2005).
25.
Moyer VA. U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 158(1), 47–54 (2013).
26.
North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 19(3), 257–271 (2012).
27.
Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obs. Gynecol. 120(3), 595–603 (2012).
28.
Stagnitti MN, Lefkowitz D. Trends in hormone replacement therapy drugs utilization and expenditures for adult women in the U.S. civilian noninstitutionalized population, 2001–2008 (2011). https://meps.ahrq.gov/data_stats/Pub_ProdResults_Details.jsp?pt=Statistical+Brief&opt=1&id=1026.
29.
Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 19(6), 616–621 (2012).
30.
Rand Europe; the Health Economics Research Group at Brunel University and King's College London. Medical Research: What's it worth? Estimating the economic benefits of cancer-related research in the UK. Briefing document (2014). https://wellcome.ac.uk/sites/default/files/wtp056595_0.pdf.
31.
Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 367(9519), 1319–1327 (2006).
• Evaluation of the US National Institutes of Health clinical trials program.
32.
Soeters M, Verhoeks G. Kostenbesparingen door onderzoek en innovatie in de zorg (2013). www.zonmw.nl/uploads/tx_vipublicaties/Notitie_Kostenbesparingen_door_onderzoek_en_innovatie_in_de_zorg_02.pdf.
33.
Access Economics. Exceptional Returns: The Value of Investing In Health R&D in Australia (2003). www.asmr.org.au/Except.pdf.
34.
Access Economics. Exceptional Returns: The Value of Investing in Health R&D in Australia II (2008). www.asmr.org.au/ExceptII08.pdf.
35.
Deloitte Access Economics. Extrapolated returns on investment in NHMRC medical research (2012). www.asmr.org.au/ExtrapolatedNHMRC12.pdf.
36.
Blakemore C, Davidson J. Putting a value on medical research. Lancet 367(9519), 1293–1295 (2006).
37.
Büro Für Technikfolgen-Abschätzung Beim Deutschen Bundestag (Tab). Stand und Bedingungen klinischer Forschung in Deutschland un im Vergleich zu anderen Ländern unter besondere Berücksichtigung nichtkommerzieller Studien. Innovationsreport. Arbeitsbericht nr. 135. (2010). http://dipbt.bundestag.de/dip21/btd/17/039/1703951.pdf.
38.
Sinacki M, Jassem J, Van Tienhoven G. Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised Phase III study (EORTC 10974/22002, LAMANOMA) – why did this study fail? Euro. J. Cancer 41(18), 2787–2788 (2005).
39.
Jenkins V, Fallowfield L, Solis-Trapala I, Langridge C, Farewell V. Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme. BMJ 330(7488), 400 (2005).
40.
Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Brit. J. Cancer 82(11), 1783–1788 (2000).
41.
The Synergism Or Long Duration (SOLD) Study (SOLD). https://clinicaltrials.gov/ct2/show/NCT00593697.
42.
Somkin CP, Altschuler A, Ackerson L et al. Organizational barriers to physician participation in cancer clinical trials. Am. J. Manage. Care 11(7), 413–421 (2005).
43.
Dellapasqua S, Castiglione-Gertsch M. Why did the study fail? Eur. J. Cancer 41(18), 2784–2786 (2005).
44.
Fallowfield L, Ratcliffe D, Souhami R. Clinicians’ attitudes to clinical trials of cancer therapy. Eur. J. Cancer 33(13), 2221–2229 (1997).
45.
ECRIN. www.ecrin.org.
46.
Christensen M, Knop FK. The unobtainable placebo: control of independent clinical research by industry? Lancet 379(9810), 30 (2012).
47.
Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N. Engl. J. Med. 370(16), 1478–1481 (2014).
48.
Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933–980 (2011).
49.
Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published. BMJ 346, f105 (2013).
50.
Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N. Engl. J. Med. 372(11), 1031–1039 (2015).
51.
Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 6(9), e1000144 (2009).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 5 September 2016
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Publicly funded practice-oriented clinical trials: of importance for healthcare payers. (2016) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2016-0018
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Denis Lacombe, Fábio Cardoso Borges, Ana E. Amariutei, Christopher M. Booth, Guy Brusselle, Raffaella Casolino, Pierre Demolis, Rosa Giuliani, Daniel A. Goldstein, Gwenaelle Gravis, Martin Kaiser, Iphigenie Korakis, Momir Radulovic, Richard Sullivan, Bertrand Tombal, Beate Wieseler, Michael Zaiac, Caroline Voltz-Girolt, Francesco Pignatti, Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum, Journal of Cancer Policy, 10.1016/j.jcpo.2025.100700, 47, (100700), (2026).
- Frank Hulstaert, Jillian Harrison, Hilde Nevens, Nelle Stocquart, Elisabeth Marynen, Céline Pouppez, Mattias Neyt, Leen Verleye, France Vrijens, Good clinical trial funding practices: how can public funders reduce the risk of trial failure and improve health impact?, Trials, 10.1186/s13063-026-09511-y, (2026).
- Jarir At Thobari, Eggi Arguni, Janis Asuncion Bunoan-Macazo, Stephanie Clark, Narangerel Dorj, Vannida Douangboupha, Pawinee Doungngern, Ha Hai Vu, Lukman Ade Chandra, Jonathan Hasian Haposan, Isireli Koroituku, Phonethipsavanh Nouanthong, Anna Lisa Ong-Lim, Dashpagam Otgonbayar, Linh Phuong Tran, Ilisapeci Tuibeqa, Claire von Mollendorf, Fiona M. Russell, Opportunities and challenges of conducting vaccine research in low and middle-income countries in the Asia–Pacific region: perspectives from the Asia–Pacific Vaccine Research Network, The Lancet Regional Health - Western Pacific, 10.1016/j.lanwpc.2025.101559, 58, (101559), (2025).
- Fábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, Stefan Aebi, Ana E Amariutei, Justin Bekelman, Thierry Gorlia, Frank Hulstaert, Isabelle Huys, Paul Kluetz, Michael J Morris, Vijay Patil, Sheila A Prindiville, Richard L Schilsky, Andrew Thomson, Shaun Treweek, Michael Weller, Mira Zuidgeest, Valesca Retel, Denis Lacombe, Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer, The Lancet Oncology, 10.1016/S1470-2045(24)00756-3, 26, 5, (e253-e263), (2025).
- Marta del Álamo, Sabrina Lémeret, Cristina Nieto, Lara Pandya, Hans Hagen, Saul Walker, Jacques Demotes, Funding multinational investigator-initiated clinical studies in Europe: why and how?, Trials, 10.1186/s13063-024-08548-1, 25, 1, (2024).
- Robbe Saesen, Kevin Depreytere, Karyna Krupianskaya, Joël Langeweg, Julie Verheecke, Denis Lacombe, Isabelle Huys, Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments, BMC Medical Research Methodology, 10.1186/s12874-023-01975-9, 23, 1, (2023).
- Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Zilke Claessens, Thomas Desmet, Evelien De Sutter, Laurenz Govaerts, Rosanne Janssens, Teodora Lalova, Evelien Moorkens, Robbe Saesen, Elise Schoefs, Yannick Vandenplas, Eline Van Overbeeke, Ciska Verbaanderd, Isabelle Huys, How to balance valuable innovation with affordable access to medicines in Belgium?, Frontiers in Pharmacology, 10.3389/fphar.2022.960701, 13, (2022).
- C. Madeira, L. Hořavová, F. dos Santos, J. R. Batuca, K. Nebeska, L. Součková, C. Kubiak, J. Demotes, R. Demlová, E. C. Monteiro, Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes, Therapeutic Innovation & Regulatory Science, 10.1007/s43441-021-00293-w, 55, 5, (966-978), (2021).
- Lauren Leddy, Prasanth Sukumar, Lydia O’Sullivan, Fionnuala Keane, Declan Devane, Peter Doran, An investigation into the factors affecting investigator-initiated trial start-up in Ireland, Trials, 10.1186/s13063-020-04893-z, 21, 1, (2020).
- Mattias Neyt, Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water, PharmacoEconomics, 10.1007/s40273-017-0566-5, 36, 1, (1-3), (2017).